Ultimate Longevity Peptide Stack: Epithalon, MOTS-c, Humanin, and GHK-Cu

Longevity medicine has moved beyond theoretical frameworks into practical, measurable interventions. The compounds that have emerged from mitochondrial genetics, telomere biology, and cellular repair research represent the most mechanistically sophisticated longevity tools currently available outside of active pharmaceutical trials. For 2026, a small but powerful group of peptides sits at the intersection of these research frontiers.

The ultimate longevity peptide stack — epithalon, MOTS-c, humanin, and GHK-Cu — addresses the four most critical hallmarks of biological aging: telomere shortening, mitochondrial dysfunction, neurodegeneration, and systemic tissue deterioration. This is not a performance stack. It is a biological maintenance protocol designed to extend health span by preserving the molecular machinery that aging degrades.

The Four Longevity Peptides: Mechanisms

Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) based on the pineal gland polypeptide epithalamin. As the only known non-enzyme-based telomerase activator that has been studied in humans, epithalon occupies a unique position in longevity research. Published studies from the St. Petersburg Institute of Bioregulation and Gerontology spanning 40+ years document the following in human and animal models: telomere elongation in culture and in vivo, extended lifespan in animal models (up to 33% in certain studies), restoration of circadian melatonin rhythms, reduced oxidative stress markers, decreased incidence of spontaneous tumors, and normalization of HPA axis function in elderly subjects.

Perhaps most significantly, the Khavinson group's 15-year follow-up study of elderly patients who received epithalamin treatment showed a 1.6-2.5x reduction in mortality compared to control groups — one of the most striking longevity statistics in published peptide research. Epithalon's synthetic version replicates the active component of this effect.

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino acid peptide encoded not by nuclear DNA but by mitochondrial DNA — specifically from a small open reading frame within the 12S rRNA gene. Discovered in 2015 by a research group at USC, it was the first mitochondria-derived peptide (MDP) to be identified and has since become one of the most exciting subjects in longevity biology.

MOTS-c's primary function is the regulation of metabolic flexibility — the ability to efficiently switch between glucose and fat metabolism. It activates AMPK (a master metabolic regulator), suppresses the folate cycle to redirect one-carbon metabolism toward AMPK activation, reduces insulin resistance, and increases mitochondrial biogenesis. In aging animal models, MOTS-c supplementation reverses multiple hallmarks of metabolic aging, extends lifespan, and restores the metabolic profile of older animals to resemble younger ones. Circulating MOTS-c levels decline significantly with age, and this decline correlates with metabolic disease risk.

Humanin is another mitochondria-derived peptide, discovered through an unusual route: researchers searching for proteins that protect against Alzheimer's disease found it expressed from a small open reading frame in the mitochondrial 16S rRNA region. Humanin is primarily characterized as a cytoprotective and neuroprotective factor. It protects neurons against amyloid-beta toxicity, reduces apoptosis (programmed cell death) in response to cellular stress, activates JAK-STAT signaling to promote cell survival, and has significant anti-inflammatory effects via NF-kB inhibition.

Circulating humanin levels decline dramatically with age — a 40-year-old has roughly half the humanin of a 25-year-old — and low humanin is associated with cardiovascular disease, cognitive decline, and reduced longevity. In animal models, humanin supplementation extends lifespan, reduces neurodegeneration, and preserves metabolic function. Unlike most peptides, humanin appears to act both within cells (intracellular signaling) and as a circulating systemic factor, giving it unusual reach across multiple organ systems.

GHK-Cu (copper peptide glycyl-histidyl-lysine-copper) serves as the tissue regeneration and repair pillar of this longevity stack. As detailed in our anti-aging peptide stack guide, GHK-Cu activates over 4,000 genes predominantly in the direction of healing, regeneration, and anti-inflammatory processes. In the context of a longevity protocol, GHK-Cu addresses the progressive accumulation of tissue damage that characterizes biological aging — the gradual degradation of collagen matrices, wound healing capacity, and tissue remodeling efficiency that makes older bodies more fragile.

The Quarterly Cycling Protocol

The longevity stack is designed for long-term use and is structured quarterly to align with natural seasonal variations in biology, maintain receptor sensitivity, and allow for comprehensive assessment between cycles.

Quarter 1 (Months 1–3): Active Longevity Cycle

Epithalon:

• Dose: 100 mcg per injection
• Course: 10 consecutive daily injections in week 1 of the quarter (1,000 mcg total per course)
• Route: Subcutaneous injection
• Then pause epithalon for remainder of quarter

MOTS-c:

• Dose: 10 mg per week
• Frequency: 2 injections per week (5 mg each, e.g., Monday and Thursday)
• Route: Subcutaneous injection
• Duration: Weeks 1–10 (10 weeks on)

Humanin:

• Dose: 2 mg per injection
• Frequency: 3x per week (e.g., Monday, Wednesday, Friday)
• Route: Subcutaneous injection
• Duration: Weeks 1–10 (10 weeks on)

GHK-Cu:

• Subcutaneous: 1 mg daily, 5 days on, 2 off
• Topical: 1–3% serum applied to face, neck, and any areas of skin concern, twice daily
• Duration: Continuous throughout the active cycle; topical can continue through off quarter

Quarter 2 (Month 4): Off Quarter

• All injectable peptides paused
• Topical GHK-Cu may continue
• Focus: Biomarker assessment, recovery, optimization of lifestyle foundations
• Key measurements: Epigenetic age test (GrimAge, DunedinPACE), IGF-1, hsCRP, telomere length (if budget permits), comprehensive metabolic panel

Quarters 3 and 4: Repeat the active/off cycle structure

Biomarker Tracking for Longevity Protocols

Unlike performance-focused stacks where results are felt subjectively within weeks, longevity protocol benefits are measured in biological age markers that require specific testing:

Epigenetic clock testing: Services like TruDiagnostic (TruAge) or Elysium Index measure biological age from DNA methylation patterns. GrimAge and DunedinPACE (a measure of aging pace rather than current age) are the most predictive of health outcomes. Testing annually or between cycles allows objective assessment of whether the protocol is shifting biological aging rate.

Telomere length: Available through SpectraCell Laboratories and similar specialty labs. Meaningful changes take years to accumulate, so this is a multi-year longitudinal marker rather than a cycle-to-cycle metric.

Inflammatory markers: hsCRP (high-sensitivity C-reactive protein) and IL-6 are practical inflammatory aging markers available through standard labs. Significant reductions indicate meaningful progress.

Metabolic markers: Fasting glucose, HbA1c, fasting insulin, and HOMA-IR assess the metabolic aging component targeted by MOTS-c. Improvement in these markers on the longevity stack is expected.

Lipid particle sizing (NMR LipoProfile): Standard lipid panels miss particle size data. Small LDL particles are far more atherogenic than large particles at the same LDL concentration. MOTS-c and humanin both affect lipid metabolism — NMR lipoprotein testing provides more granular data on cardiovascular aging status.

See our comprehensive guide to blood tests for nutrition and supplements for how to order and interpret these panels.

Lifestyle Pillars That Amplify the Longevity Stack

Peptides are potent tools, but they amplify an established foundation rather than substitute for it. The longevity literature is unambiguous about the pillars that interact most powerfully with the compounds in this stack:

Fasting and time-restricted eating: Caloric restriction and intermittent fasting activate AMPK — the same pathway MOTS-c stimulates. The two approaches are synergistic rather than redundant. A 16:8 intermittent fasting protocol (eating within an 8-hour window) during active cycles amplifies MOTS-c's metabolic effects substantially.

Resistance training: Maintains muscle mass (sarcopenia is one of the strongest predictors of mortality in older adults), stimulates GH secretion that synergizes with the repair-oriented peptides, and reduces the chronic inflammation that humanin and GHK-Cu work against. 3–4 sessions per week of resistance training is the minimum meaningful dose.

Sleep optimization: GH is released during delta sleep, epithalon normalizes melatonin and circadian rhythms, and humanin's neuroprotective effects are most pronounced during the brain's overnight repair processes. Prioritizing 7.5–9 hours of sleep per night is non-negotiable for a longevity protocol.

Rapamycin (consideration for advanced users): The mTOR inhibitor rapamycin has among the strongest longevity evidence of any compound in mammals — it extends lifespan in mice regardless of when it is initiated. Some longevity-focused physicians prescribe low-dose weekly rapamycin (typically 5–10 mg) alongside peptide protocols. MOTS-c and rapamycin may interact through AMPK-mTOR crosstalk — this combination is beyond the scope of general guidance and requires physician supervision.

Costs and Practical Considerations

This is not an inexpensive protocol. Rough monthly costs at current (2026) pricing:

• MOTS-c: $200–350/month
• Humanin: $150–250/month
• GHK-Cu injectable: $80–120/month
• Epithalon: $40–80/course (quarterly)
• GHK-Cu topical: $30–60/month

Total monthly cost during active cycles: $500–800+. The quarterly off-period reduces annualized costs. For those interested in a more accessible starting point, the anti-aging stack with epithalon and GHK-Cu covers the most studied compounds at lower cost.

Frequently Asked Questions

Q: How is this longevity stack different from the anti-aging stack? The anti-aging stack uses epithalon + GHK-Cu + ipamorelin with a focus on accessible entry-level longevity intervention. This ultimate longevity protocol adds MOTS-c and humanin — mitochondrial peptides with the strongest evidence for addressing the metabolic and neuroprotective aspects of aging — and is designed for those committed to a comprehensive, sustained longevity intervention. It is more expensive, more complex, and more evidence-dense.

Q: What age should someone start this protocol? This protocol is most appropriate for those 40+, when MOTS-c, humanin, and GH decline become physiologically significant and when the biological investment in repair and maintenance has the greatest return on investment. Using these compounds in younger decades is unlikely to be harmful, but the benefit-cost ratio is lower when the biological systems they support are still functioning optimally.

Q: Can I combine this longevity stack with the immune peptide stack? Yes. Thymosin alpha-1 and LL-37 from the immune support stack have no known interactions with the longevity peptides and address a complementary aspect of biological aging (immune senescence). Running the immune stack during the off-quarter of the longevity protocol provides year-round peptide coverage with no overlap and manageable injection burden.

Q: How do I measure whether the protocol is working? Epigenetic clock testing (before and 12 months after starting) is the most direct measurement of biological aging rate change. Metabolic markers (glucose, insulin, HbA1c) and inflammatory markers (hsCRP, IL-6) provide shorter-term feedback that MOTS-c and humanin are producing biological effects. Subjective improvements in energy, cognitive clarity, and physical resilience are meaningful early signals, though they are difficult to distinguish from placebo without objective testing.

Q: Are MOTS-c and humanin peptides available commercially? Both MOTS-c and humanin are available from research peptide vendors that provide HPLC-verified products. They are not licensed pharmaceuticals in most countries and exist in the same regulatory gray area as other research peptides. Quality verification through third-party certificates of analysis is essential, as these are relatively novel compounds and supply quality varies significantly.